Hepatology highlights
Jean‐François Dufour – 24 August 2015
Hepatosplenic candidiasis
Oliver A. Cornely, Christopher Bangard, Natalie I. Jaspers – 24 August 2015 – Watch a video presentation of this article
Issues in the end‐stage liver disease patient for which palliative care could be helpful
Paula Cox‐North – 24 August 2015 – Watch a video presentation of this article
Hepatitis C treatment: Back to the warehouse
John P. Rice – 24 August 2015 – Watch a video presentation of this article
Combined effect of donor and recipient risk on outcome after liver transplantation: Research of the Eurotransplant database
Joris J. Blok, Hein Putter, Xavier Rogiers, Bart van Hoek, Undine Samuel, Jan Ringers, Andries E. Braat, Eurotransplant Liver Intestine Advisory Committee – 20 August 2015 – Recently the Eurotransplant donor risk index (ET‐DRI) was published, a model based on data from the Eurotransplant database that can be used for risk indication of liver donors within the Eurotransplant region. Because outcome after liver transplantation (LT) depends both on donor and recipient risk factors, a combined donor‐recipient model (DRM) would give a more complete picture of the overall risk involved.
Outcomes for liver transplant candidates listed with low model for end‐stage liver disease score
Allison J. Kwong, Jennifer C. Lai, Jennifer L. Dodge, John P. Roberts – 20 August 2015 – The Model for End‐Stage Liver Disease (MELD) score, which estimates mortality within 90 days, determines priority for liver transplantation (LT). However, longer‐term outcomes on the wait list for patients who are initially listed with low MELD scores are not well characterized. All adults listed for primary LT at a single, high‐volume center from 2005 to 2012 with an initial laboratory MELD score of 22 or lower were evaluated.
Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
Palak J. Trivedi, Christophe Corpechot, Albert Pares, Gideon M. Hirschfield – 20 August 2015 – Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to their incidence and prevalence, remain very important causes of morbidity and mortality for patients with liver disease.
Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
Palak J. Trivedi, Christophe Corpechot, Albert Pares, Gideon M. Hirschfield – 20 August 2015 – Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to their incidence and prevalence, remain very important causes of morbidity and mortality for patients with liver disease.
Ex vivo pancreaticoduodenectomy and liver autotransplantation for pancreatic head tumor with extensive involvement of the hepatoduodenal ligament
Nobuhide Matsuoka, Joshua I. Weiner, Adam D. Griesemer, Benjamin B. Samstein, Yejun Zhao, Jean C. Emond, Tomoaki Kato – 20 August 2015
Hepatic stellate cells regulate liver immunity to visceral leishmaniasis through P110δ‐dependent induction and expansion of regulatory T cells in mice
Forough Khadem, Xiaoling Gao, Zhirong Mou, Ping Jia, Hesamaldin Movassagh, Chukwunonso Onyilagha, Abdelilah S. Gounni, Matthew C. Wright, Jude E. Uzonna – 20 August 2015 – Visceral leishmaniasis (VL) is associated with severe immune dysfunction and if untreated leads to death. Because the liver is one of the primary target organs in VL, unraveling the mechanisms governing the local hepatic immune response is important for understanding the immunopathogenesis of VL.